|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/03/22 Aclaris Therapeutics, Inc. 10-Q 6/30/22 72:7.6M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.76M
2: EX-10.1 Material Contract HTML 117K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
11: R1 Document and Entity Information HTML 72K
12: R2 Condensed Consolidated Balance Sheets HTML 123K
13: R3 Condensed Consolidated Balance Sheets HTML 37K
(Parenthetical)
14: R4 Condensed Consolidated Statements of Operations HTML 100K
and Comprehensive Loss
15: R5 Condensed Consolidated Statements of Operations HTML 22K
and Comprehensive Loss (Parenthetical)
16: R6 Condensed Consolidated Statements of Stockholders' HTML 96K
Equity
17: R7 Condensed Consolidated Statements of Stockholders' HTML 24K
Equity (Parenthetical)
18: R8 Condensed Consolidated Statements of Cash Flows HTML 90K
19: R9 Organization and Nature of Business HTML 28K
20: R10 Summary of Significant Accounting Policies HTML 32K
21: R11 Fair Value of Financial Assets and Liabilities HTML 172K
22: R12 Property and Equipment, Net HTML 40K
23: R13 Intangible Assets HTML 59K
24: R14 Accrued Expenses HTML 35K
25: R15 Debt HTML 27K
26: R16 Stockholders' Equity HTML 34K
27: R17 Stock-Based Awards HTML 123K
28: R18 Net Loss per Share HTML 57K
29: R19 Leases HTML 42K
30: R20 Agreements Related to Intellectual Property HTML 27K
31: R21 Income Taxes HTML 25K
32: R22 Discontinued Operations HTML 31K
33: R23 Segment Information HTML 137K
34: R24 Legal Proceedings HTML 28K
35: R25 Summary of Significant Accounting Policies HTML 39K
(Policies)
36: R26 Fair Value of Financial Assets and Liabilities HTML 169K
(Tables)
37: R27 Property and Equipment, Net (Tables) HTML 38K
38: R28 Intangible Assets (Tables) HTML 60K
39: R29 Accrued Expenses (Tables) HTML 34K
40: R30 Stock-Based Awards (Tables) HTML 123K
41: R31 Net Loss per Share (Tables) HTML 58K
42: R32 Leases (Tables) HTML 40K
43: R33 Discontinued Operations (Tables) HTML 33K
44: R34 Segment Information (Tables) HTML 131K
45: R35 Organization and Nature of Business (Details) HTML 27K
46: R36 Summary of Significant Accounting Policies HTML 26K
(Details)
47: R37 Fair Value of Financial Assets and Liabilities HTML 52K
(Details)
48: R38 Fair Value of Financial Assets and Liabilities - HTML 46K
By Type (Details)
49: R39 Property and Equipment, Net (Details) HTML 41K
50: R40 Intangible Assets (Details) HTML 39K
51: R41 Intangible Assets - Future Amortization Expenses HTML 41K
(Details)
52: R42 Accrued Expenses (Details) HTML 32K
53: R43 Debt (Details) HTML 32K
54: R44 Stockholders' Equity (Details) HTML 46K
55: R45 Stockholders' Equity - Other Offerings and ATM HTML 44K
Facility (Details)
56: R46 Stock-Based Awards (Details) HTML 65K
57: R47 Stock-Based Awards - Option Activity (Details) HTML 77K
58: R48 Stock-Based Awards - RSUs (Details) HTML 46K
59: R49 Stock-Based Awards - Compensation (Details) HTML 42K
60: R50 Net Loss per Share (Details) HTML 52K
61: R51 Net Loss per Share - Anti-dilution (Details) HTML 28K
62: R52 Leases (Details) HTML 47K
63: R53 Agreements Related to Intellectual Property HTML 44K
(Details)
64: R54 Income Taxes (Details) HTML 25K
65: R55 Discontinued Operations - Assets and Liabilities HTML 27K
(Details)
66: R56 Segment Information (Details) HTML 59K
67: R57 Legal Proceedings (Details) HTML 28K
70: XML IDEA XML File -- Filing Summary XML 127K
68: XML XBRL Instance -- acrs-20220630x10q_htm XML 1.91M
69: EXCEL IDEA Workbook of Financial Reports XLSX 111K
7: EX-101.CAL XBRL Calculations -- acrs-20220630_cal XML 131K
8: EX-101.DEF XBRL Definitions -- acrs-20220630_def XML 502K
9: EX-101.LAB XBRL Labels -- acrs-20220630_lab XML 1.04M
10: EX-101.PRE XBRL Presentations -- acrs-20220630_pre XML 728K
6: EX-101.SCH XBRL Schema -- acrs-20220630 XSD 130K
71: JSON XBRL Instance as JSON Data -- MetaLinks 334± 516K
72: ZIP XBRL Zipped Folder -- 0001558370-22-011757-xbrl Zip 314K
Exhibit 31.2
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Frank Ruffo, certify that:
1. | I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2022 of Aclaris Therapeutics, Inc. (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: August 3, 2022
| |
| /s/ Frank Ruffo |
| |
| Chief Financial Officer |
| (principal financial officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/3/22 | 8-K | ||
| For Period end: | 6/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/27/24 Aclaris Therapeutics, Inc. 10-K 12/31/23 91:11M Toppan Merrill Bridge/FA 2/23/23 Aclaris Therapeutics, Inc. 10-K 12/31/22 88:11M Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/01/22 Aclaris Therapeutics, Inc. 8-K:5,9 8/01/22 11:308K Toppan Merrill Bridge/FA 6/24/20 Aclaris Therapeutics, Inc. 8-K:5,9 6/23/20 2:181K Toppan Merrill Bridge/FA 10/13/15 Aclaris Therapeutics, Inc. 8-K:5 10/13/15 3:240K Toppan Merrill/FA |